Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The receptors, found in so-called elite controllers who don’t need medications to keep the virus in check, suggest a new path toward immunotherapy.

Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice.

The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.

Merck’s Keytruda extended the lives of lung cancer patients by several months and appeared to stop the progression of advanced melanoma.  

Women with metastatic cancer who were treated with a checkpoint inhibitor had a smaller benefit than did men.